KLK3 and neoplasm: A large body of literatures exists on guidelines suggested for clinical application in various malignancies by professional bodies like American Society of Clinical Oncology,[12, 13] Canadian Task Force,[29] American Association for Clinical Chemistry,[1] etc., but the only tumor marker that finds a place in any screening algorithm is prostate-specific antigen (PSA).